Clinical Trials › NCT03783416
RecruitingPhase 1
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
Sponsored by Queen Mary University of London
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 72
Target enrollment
Jun 2020
Start date
Jul 2026
Expected completion
Interventions / Treatments
Ixazomib (NINLARO®) capsules / Matching placebo capsules
Conditions studied
Relapsing Remitting Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 1 trials
Browse all Phase 1 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.